Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Ongoing Clinical Trials

Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

E Hamilton, V Borges, R Murthy, C Anders, D Cameron, L Carey, V Müller, G Curigliano, K Gelmon, G Hortobagy, I Krop, S Loibl, X Pivort, M Pegram, D Slamon, S Hurvitz, M Tsai and E Winer
E Hamilton
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V Borges
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R Murthy
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C Anders
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Cameron
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L Carey
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V Müller
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Curigliano
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K Gelmon
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G Hortobagy
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I Krop
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Loibl
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
X Pivort
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Pegram
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D Slamon
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Hurvitz
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M Tsai
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E Winer
Sarah Cannon Research Institute, Nashville, TN; Tennessee Oncology, PLLC, Nashville, TN; University of Colorado Cancer Center, Aurora, CO; The University of Texas MD Anderson Cancer Center, Houston, TX; University of North Carolina at Chapel Hill, Chapel Hill, NC; Oncology, Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Drug Development, Istituto Europeo di Oncologia, Milano, Italy; British Columbia Cancer Agency, Vancouver Cancer Centre, Vancouver, BC, Canada; Dana-Farber Cancer Institute, Boston, MA; Medicine and Research, German Breast Group, Neu-Isenburg, Germany; Service Oncologie Medicale, CHU Besançon, Hôpital Jean Minjoz, Besançon, France; The University of California Los Angeles, Los Angeles, CA; U.C.L.A. School of Medicine, Los Angeles, CA; University of California, Los Angeles (UCLA), Los Angeles, CA; Virginia Piper Cancer Institute, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.SABCS16-OT1-02-09 Published February 2017
  • Article
  • Info & Metrics
Loading
Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas

Abstract

Background: ONT-380 is a highly selective small molecule inhibitor of HER2 kinase with nanomolar potency. Unlike dual HER2/EGFR agents, it does not inhibit EGFR at clinically relevant concentrations, decreasing the potential for EGFR-related toxicities (severe skin rash and diarrhea). In preclinical studies, ONT-380 demonstrated synergistic activity with T, and was active in HER2+ models of brain metastases (mets). In a Phase 1b study, ONT-380 was combined with C and T in pts with HER2+ MBC previously treated with trastuzumab emtansine (T-DM1) and T. Objective responses were seen, including in pts with brain mets. The combination was well tolerated, with low rates of Gr 3 diarrhea at the recommended dose (300 mg PO BID, equivalent to the single agent MTD). Based on these data, ONT-380 is now being evaluated in a Phase 2 study in combination with C and T (HER2CLIMB).

Trial Design: The primary study objective is to assess the effect of ONT-380 vs. placebo given with C + T on progression-free survival (PFS) based on independent central review. Additional objectives include ORR, duration of response, clinical benefit rate, and safety. The study population includes adult pts with progressive HER2+ locally advanced or MBC who have had prior treatment with a taxane, T, pertuzumab and T-DM1 but not C or lapatinib. Pts with brain mets,including untreated or progressive mets, may be enrolled. 180 pts will be enrolled in North America and Europe. Pts are receiving C (1000 mg/mg2 PO BID for 14 days of a 21-day cycle) and T (8 mg/kg IV loading dose; 6 mg/kg IV once every 21 days), and are being randomized in a 2:1 ratio to ONT-380 300 mg PO BID or placebo. Pts with isolated CNS progression may continue on study treatment after undergoing local CNS therapy. An independent Data Monitoring Committee is monitoring pt safety.

Citation Format: Hamilton E, Borges V, Murthy R, Anders C, Cameron D, Carey L, Müller V, Curigliano G, Gelmon K, Hortobagy G, Krop I, Loibl S, Pivort X, Pegram M, Slamon D, Hurvitz S, Tsai M, Winer E. A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-02-09.

Previous
Back to top
Cancer Research: 77 (4 Supplement)
February 2017
Volume 77, Issue 4 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC…
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)
E Hamilton, V Borges, R Murthy, C Anders, D Cameron, L Carey, V Müller, G Curigliano, K Gelmon, G Hortobagy, I Krop, S Loibl, X Pivort, M Pegram, D Slamon, S Hurvitz, M Tsai and E Winer
Cancer Res February 15 2017 (77) (4 Supplement) OT1-02-09; DOI: 10.1158/1538-7445.SABCS16-OT1-02-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)
E Hamilton, V Borges, R Murthy, C Anders, D Cameron, L Carey, V Müller, G Curigliano, K Gelmon, G Hortobagy, I Krop, S Loibl, X Pivort, M Pegram, D Slamon, S Hurvitz, M Tsai and E Winer
Cancer Res February 15 2017 (77) (4 Supplement) OT1-02-09; DOI: 10.1158/1538-7445.SABCS16-OT1-02-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Ongoing Clinical Trials

  • Abstract OT3-06-03: ABC-SE, Advanced Breast Cancer – Statins and Endocrine treatment
  • Abstract OT1-06-03: The plasmaMATCH trial: A multiple parallel cohort, open-label, multi-centre phase II clinical trial of ctDNA screening to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010)
  • Abstract OT2-07-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)
Show more 3

Her2

  • Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer
  • Abstract OT1-03-04: A phase II study of neoadjuvant aromatase inhibitor with pertuzumab and trastuzumab for patients with ER+HER2+ stage I-II breast cancer (NEOADAPT)
  • Abstract OT1-03-05: The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement